MorphoSys expands Bristol-Myers Squibb agreement

Published: 27-Jan-2005

MorphoSys has further expanded its existing licence agreement with Bristol-Myers Squibb (B-MS). Under the amended agreement, MorphoSys grants B-MS access to its HuCAL GOLD library for use in pharmaceutical discovery programmes for target characterisation and validation, as well as for therapeutic and diagnostic antibody product development.


MorphoSys has further expanded its existing licence agreement with Bristol-Myers Squibb (B-MS). Under the amended agreement, MorphoSys grants B-MS access to its HuCAL GOLD library for use in pharmaceutical discovery programmes for target characterisation and validation, as well as for therapeutic and diagnostic antibody product development.

Prior to the most recent expansion, B-MS had a non-exclusive license to use prior versions of MorphoSys' HuCAL library and the AutoCAL system, MorphoSys' established system for fully automated high-throughput antibody generation.

In addition, B-MS has an option to further develop promising antibody candidates arising from these programmes as therapeutics and diagnostics.

Financial details were not disclosed

  

You may also like